Chemotherapeutic treatments: A study of the interplay among drug resistance, toxicity and recuperation from side effects
From MaRDI portal
Publication:1361432
DOI10.1007/BF02462001zbMath0899.92024MaRDI QIDQ1361432
José Luiz Boldrini, M. I. S. Costa
Publication date: 1997
Published in: Bulletin of Mathematical Biology (Search for Journal in Brave)
49N70: Differential games and control
92C50: Medical applications (general)
93C15: Control/observation systems governed by ordinary differential equations
49N75: Pursuit and evasion games
Related Items
TUMOR/IMMUNE SYSTEM COMPETITION WITH MEDICALLY INDUCED ACTIVATION/DEACTIVATION, TUMOR/IMMUNE SYSTEM COMPETITION WITH MEDICALLY INDUCED ACTIVATION/DEACTIVATION, A survey of optimization models on cancer chemotherapy treatment planning, Conflicting objectives in chemotherapy with drug resistance, The dynamics of an optimally controlled tumor model: A case study, Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures, The dynamics of war between benign cells, malignant cells, and killer agents
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Optimal control for a cancer chemotherapy problem with general growth and loss functions
- Role of optimal control theory in cancer chemotherapy
- A model for the resistance of tumor cells to cancer chemotherapeutic agents
- Optimal control analysis in the chemotherapy of IgG multiple myeloma
- Mathematical approaches to optimization of cancer chemotherapy
- Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis
- Dynamics of tumor interaction with the host immune system
- Tumor growth \textit{in vivo} and as multicellular spheroids compared by mathematical models
- Drug kinetics and drug resistance in optimal chemotherapy
- Chemotherapeutic treatments involving drug resistance and level of normal cells as a criterion of toxicity
- Some optimal control problems in cancer chemotherapy with a toxicity limit
- A stochastic model for the origin and treatment of tumors containing drug-resistant cells
